Business Wire

NY-REVBITS

22.5.2023 15:16:25 CEST | Business Wire | Press release

Share
RevBits Completes Development for its Privileged Access Management Solution to be Fully Deployable in a True Air Gapped Environment

RevBits announces that it has successfully completed the architectural development of its privileged access management solution for deployment in a true air gapped environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005003/en/

RevBits Privileged Access Management (RB/PAM) is an advanced access management solution that includes seven modules and extensive session logging that captures keystrokes and video. These unique access control capabilities and multi-module offerings reduce vendor relationship management efforts and increase access management safeguards.

RevBits PAM has two U.S. patents - a browser-based zero-knowledge encryption and authentication authority that extends to various hardware security solutions.

RevBits PAM modules:

Privileged Access Management - regulates access to critical resources, captures keystrokes, and video records all privileged sessions.

Privileged Session Management - provides keystroke and query logging for all sessions through the solution's Jump Server.

Password Management - extends authentication security with hardware security modules, USB tokens, smart cards, near-field communications, and RFID.

Service Account Management - scans and onboards service accounts and scheduled tasks for IIS web applications.

Key Management - allows users to easily generate and store encryption keys.

Certificate Management - reports all expired or soon-to-expire certificates and vulnerable implementations of SSL.

CI/CD Integration - the CI/CD module plugs into your current platform and unlocks the capabilities of secure secret management across the CI/CD lifecycle, allowing for easy management of CI/CD users, credentials, and assets.

Defining Air Gap:

Techopedia: "An air gap is a security measure that isolates a digital device component or private local area network (LAN) from other devices and networks, including the public internet. An air gap is also known as an air wall, and the strategy of using air gaps to protect critical data is also known as security by isolation.

Air gaps are used to protect critical computer systems and the data they store from malware, keyloggers, ransomware, and other types of unauthorized access. This strategy seeks to ensure the total isolation of a given system electromagnetically, electronically, and physically."

RevBits Privileged Access Management – our Air Gap capability:

Inside the air gap environment sit servers and assets critical to the organization. As important as it is to protect against malware and ransomware attacks, it is equally important to protect the data on those servers from malicious acts and theft in an air gap environment.

RevBits Privileged Access Management is fully featured in an air gapped environment allowing for complete server security and data protection. Server access is monitored through extensive session monitoring, including video recording and keystroke logging.

About RevBits

Established in 2018, RevBits is a comprehensive cybersecurity company dedicated to providing customers with superior protection and service. RevBits delivers protection against the most sophisticated cyber threats companies face by offering multiple advanced security capabilities that can be administered through a unified security platform. RevBits is headquartered in Mineola, NY, with offices in Princeton, NJ; Boston, MA; London, England; and Antwerp, Belgium. For more information please visit RevBits.

RevBit's complete solution suite offerings are RevBits Endpoint Security, RevBits Email Security, RevBits Privileged Access Management, RevBits Zero Trust Network, and RevBits Deception Technology. For customers running more than one RevBits solution, the administration is managed through RevBits Cyber Intelligence Platform, a unified, single-pane environment that curates, correlates, and alerts to threats while delivering intelligence for a quick administrative response. RevBits Cyber Intelligence Platform integrates with all common SIEMs.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005003/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye